Survival outcomes for patients on ipilimumab plus nivolumab combination therapy

Further results from the ongoing CheckMate 214 phase III study have been released. In this study, 550 patients with advanced renal cell carcinoma (RCC) were randomised to receive ipilimumab plus nivolumab and 546 were randomised to be treated with sunitinib. Patients with intermediate- or poor-risk RCC responded well to ipilimumab plus nivolumab and progression-free and […]

read more

ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer

Results from the phase II FRACTION-RCC clinical trial to assess the nivolumab plus ipilimumab combination in previously treated advanced renal cell carcinoma (RCC) patients were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. The study looked at 46 patients with previously treated RCC that was not responding to […]

read more

ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab

Two studies were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to investigate whether initial treatment of metastatic renal cell carcinoma (RCC) patients with nivolumab followed by the addition of ipilimumab for patients with either stable or progressive disease would be as effective as upfront combination therapy and with less side […]

read more

ASCO GU 2020: Immunotherapy combinations effective for brain metastases

Two small studies reported on patients whose kidney cancer had spread into the brain at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. The first study was a real-world report of 17 patients with advanced kidney cancer in the brain. The patients were treated with ipilimumab and […]

read more

Nivolumab/ipilimumab combination extends treatment-free survival in kidney cancer patients

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

ESMO 2019: Results from TITAN-RCC tailored immunotherapy clinical trial

Results from the TITAN-RCC clinical trial to assess tailored immunotherapy for patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. TITAN-RCC is a large phase 2 study investigating tailored immunotherapy for people with advanced RCC. Patients started with nivolumab monotherapy. The […]

read more

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month. Read more in Cancer […]

read more

SMC approves nivolumab plus ipilimumab combination for advanced RCC

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]

read more
Showing 1 to 10 of 54 results
  TOP